Loading color scheme

Ecosystem Startup


Aclys Bio discovers and develops precision biologics for the treatment of cancer. Aclys has identified a set of novel precision and immune-oncology targets from the tumor molecular profiles of tens of thousands of cancer patients and is building antibody-based therapies against each target, both for internal development, and for partnership. Aclys’s Precision ImmunoLogical Antibody™ discovery platform (PILA™ or PILA Platform™) enables Aclys’s rapid antibody engineering and optimization. The resultant new class of developable precision biologics has unique potential to decrease clinical trial times, costs, and risk, while improving trial success rates and ultimately, patient lives.​

Innovation Space:

Latest News